Your shopping cart is empty.

Free US shipping over $25 Same day shipping before 2pm est

ECIgIntelligence - BAT gets UK regulatory approval

ECigIntelligence - Britain’s medicines regulator has issued a product licence for the nicotine inhaler Voke, which will be sold by British American Tobacco’s subsidiary Nicoventures and looks likely to be the closest pharmaceutically-approved competitor to the e-cigarette.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has given the Voke Inhaler 0.45mg a licence for general sale, meaning that it can be sold in general retail outlets without the supervision of a pharmacist.

Its developer Kind Consumer – which signed an agreement with Nicoventures in 2010 for the latter to commercialise Voke – says it is “for use to relieve and/or prevent craving and nicotine withdrawal symptoms” but, significantly, adds that as well as being indicated for smokers trying to reduce or quit, it can also be used “to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them”.

The MHRA approval also means that Voke could be provided to consumers free, or via subsidised prescriptions, through the National Health Service (NHS) and its smoking cessation services.

Visually, Voke strongly resembles an e-cigarette – and indeed a tobacco cigarette – but the technology is quite different.

Instead of a nicotine-containing liquid being heated by a battery to produce a visible vapour, Voke uses pressure to atomise the nicotine. An invisible vapour is inhaled by the user through a breath-operated valve.



Barnaby Page ECigIntelligence staff

Visa, Mastercard, American Express, Discover
SSL Certificate Veratad